Clinico-Pathological Features and Immunohistochemical Comparison of p16, p53, and Ki-67 Expression in Muscle-Invasive and Non-Muscle-Invasive Conventional Urothelial Bladder Carcinoma
Abstract
:1. Introduction
2. Methods
2.1. Histological Examination
2.2. Immunohistochemical Study
2.2.1. p16(INK4A) Scoring
2.2.2. p53 Staining
2.2.3. Ki-67 Index
2.2.4. Exclusion Criteria
2.2.5. Ethical Approval
2.2.6. Statistical Analysis
3. Results
3.1. Clinico-Histological Features
3.2. Immunohistochemical Expression
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Bilim, V.; Kuroki, H.; Shirono, Y.; Murata, M.; Hiruma, K.; Tomita, Y. Advanced Bladder Cancer: Changing the Treatment Landscape. J. Pers. Med. 2022, 12, 1745. [Google Scholar] [CrossRef]
- WCRF. World Cancer Research Fund International. Available online: https://www.wcrf.org/diet-activity-and-cancer/cancer-types/bladder-cancer/ (accessed on 14 February 2023).
- Globoscan-The Global Cancer Observator. 2020. Available online: https://gco.iarc.fr/today/data/factsheets/populations/818-egypt-fact-sheets.pdf (accessed on 1 December 2022).
- Gluck, G.; Hortopan, M.; Stănculeanu, D.; Chiriță, M.; Stoica, R.; Sinescu, I. Comparative study of conventional urothelial carcinoma, squamous differentiation carcinoma and pure squamous carcinoma in patients with invasive bladder tumors. J. Med. Life 2014, 7, 211–214. [Google Scholar]
- Kaufman, D.S.; Shipley, W.U.; Feldman, A.S. Bladder cancer. Lancet 2009, 374, 239–249. [Google Scholar] [CrossRef]
- Woldu, S.L.; Bagrodia, A.; Lotan, Y. Guideline of guidelines: Non-muscle-invasive bladder cancer. BJU Int. 2017, 119, 371–380. [Google Scholar] [CrossRef] [Green Version]
- Flaig, T.W.; Spiess, P.E.; Agarwal, N.; Bangs, R.; Boorjian, S.A.; Buyyounouski, M.K.; Chang, S.; Downs, T.M.; Efstathiou, J.A.; Friedlander, T.; et al. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2020, 18, 329–354. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sanli, O.; Dobruch, J.; Knowles, M.A.; Burger, M.; Alemozaffar, M.; Nielsen, M.E.; Lotan, Y. Bladder cancer. Nat. Rev. Dis. Primers 2017, 3, 17022. [Google Scholar] [CrossRef] [Green Version]
- Helal, N.S.; Omran, Z.; Moussa, M. Assessment of survivin and p27 expression as potential prognostic markers in urothelial cell carcinoma of urinary bladder in Egyptian patients. Afr. J. Urol. 2022, 28, 45. [Google Scholar] [CrossRef]
- March-Villalba, J.A.; Ramos-Soler, D.; Soriano-Sarrió, P.; Hervás-Marín, D.; Martínez-García, L.; Martínez-Jabaloyas, J.M. Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papillary urothelial bladder cancer pTa/pT1 G2 (WHO 1973). Urol. Oncol. Semin. Orig. Investig. 2019, 37, 158–165. [Google Scholar] [CrossRef]
- Montes-Mojarro, I.A.; Hassas, S.; Staehle, S.; Sander, P.; Harland, N.; Serna-Higuita, L.M.; Bonzheim, I.; Bösmüller, H.; Stenzl, A.; Fend, F. Multiparametric Classification of Non-Muscle Invasive Papillary Urothelial Neoplasms: Combining Morphological, Phenotypical, and Molecular Features for Improved Risk Stratification. Int. J. Mol. Sci. 2022, 23, 8133. [Google Scholar] [CrossRef]
- Shariat, S.F.; Tokunaga, H.; Zhou, J.; Kim, J.; Ayala, G.E.; Benedict, W.F.; Lerner, S.P. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J. Clin. Oncol. 2004, 22, 1014–1024. [Google Scholar] [CrossRef]
- Yin, M.; Bastacky, S.; Parwani, A.V.; McHale, T.; Dhir, R. p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ. Hum. Pathol. 2008, 39, 527–535. [Google Scholar] [CrossRef]
- Raspollini, M.R.; Luque, R.J.; Menendez, C.L.; Bollito, E.; Brunelli, M.; Martignoni, G.; Montironi, R.; Cheng, L.; Blanca, A.; Baroni, G.; et al. T1 high-grade bladder carcinoma outcome: The role of p16, topoisomerase-IIα, survivin, and Ecadherin. Hum. Pathol. 2016, 57, 78–84. [Google Scholar] [CrossRef]
- Ren, Y.; Xiao, L.; Weng, G.; Shi, B. Clinical significance of p16INK4A and p14ARF promoter methylation in renal cell carcinoma: A meta-analysis. Oncotarget 2017, 8, 64385–64394. [Google Scholar] [CrossRef] [Green Version]
- Shigehara, K.; Sasagawa, T.; Doorbar, J.; Kawaguchi, S.; Kobori, Y.; Nakashima, T.; Shimamura, M.; Maeda, Y.; Miyagi, T.; Kitagawa, Y.; et al. Etiological role of human papillomavirus infection for inverted papilloma of the bladder. J. Med. Virol. 2011, 83, 277–285. [Google Scholar] [CrossRef]
- Şen Türk, N.; Aybek, Z.; Düzcan, E. Ki-67, p53, Bcl-2 and bax expression in urothelial carcinomas of urinary bladder. Turk. J. Pathol. 2010, 26, 25–30. [Google Scholar] [CrossRef] [Green Version]
- Chaudry, M.U.; Akhtar, F.; Jamal, N.; Mansur, H.; Sarwar, N.; Saleem, Y. Immunohistochemical expression of P16 in low grade urothelial carcinoma. Pak. Armed Forces Med. J. 2021, 71, 885–888. [Google Scholar] [CrossRef]
- Manini, C.; Angulo, J.C.; López, J.I. Mimickers of Urothelial Carcinoma and the Approach to Differential Diagnosis. Clin. Pract. 2021, 11, 110–123. [Google Scholar] [CrossRef] [PubMed]
- Witjes, J.A.; Lebret, T.; Compérat, E.M.; Cowan, N.C.; De Santis, M.; Bruins, H.M.; Hernández, V.; Espinós, E.L.; Dunn, J.; Rouanne, M.; et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur. Urol. 2016, 71, 462–475. [Google Scholar] [CrossRef]
- Quarles, J.; Richmond, J.; Swamy, V.; Pandey, J. Educational Case: Bladder Urothelial Cell Carcinoma TNM Stage, Prognosis and Management. Acad. Pathol. 2021, 8, 23742895211022256. [Google Scholar] [CrossRef]
- Dawood, G. Urinary system. In Color Atlas of Human Gross Pathology; Springer: Cham, Switzerland, 2022; pp. 75–91. [Google Scholar] [CrossRef]
- Batista, R.; Vinagre, N.; Meireles, S.; Vinagre, J.; Prazeres, H.; Leão, R.; Máximo, V.; Soares, P. Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review. Diagnostics 2020, 10, 39. [Google Scholar] [CrossRef] [Green Version]
- Mostofi, F.K.; Sobin, L.H.; Torloni, H. (Eds.) Histologic Typing of Urinary Bladder Tumors; World Health Organization: Geneva, Switzerland, 1973. [Google Scholar]
- Epstein, J.I.; Amin, M.B.; Reuter, V.R.; Mostofi, F.K. The world health organization international society of urological pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am. J. Surg. Pathol. 1998, 22, 1435–1448. [Google Scholar] [CrossRef]
- Mostofi, F.K.; Davis, C.J.; Sesterhenn, I.A. (Eds.) Histologic typing of urinary bladder tumors. In World Health Organization International Histologic Classification of Tumours, 14th ed.; Springer: Berlin/Heidelberg, Germany, 1999; pp. 1–29. [Google Scholar]
- Varma, M.; Delahunt, B.; van der Kwast, T. Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question. Eur. Urol. 2019, 76, 413–415. [Google Scholar] [CrossRef]
- Compérat, E.; Wasinger, G.; Oszwald, A.; Shariat, S.F. Brief update of the new WHO classification for urothelial carcinoma. Curr. Opin. Urol. 2022, 32, 511–516. [Google Scholar] [CrossRef]
- Soloway, M.; Khoury, S. Bladder cancer. In International Consultation on Bladder Cancer—Vienna, 2nd ed.; International Consultation on Urological Disease: Bristol, UK, 2012; pp. 23–342. [Google Scholar]
- Morgan, T.M.; Cookson, M.S.; Netto, G.J.; Epstein, J.I. Bladder cancer overview and staging. In The Urinary Tract: A Comprehensive Guide to Patient Diagnosis and Management; Springer: New York, NY, USA, 2012; pp. 83–112. [Google Scholar]
- Xylinas, E.; Rink, M.; Robinson, B.D.; Lotan, Y.; Babjuk, M.; Brisuda, A.; Green, D.A.; Kluth, L.A.; Pycha, A.; Fradet, Y.; et al. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. Eur. J. Cancer 2013, 49, 1889–1897. [Google Scholar] [CrossRef]
- Gandhi, J.; Chen, J.F.; Al-Ahmadie, H. Urothelial Carcinoma: Divergent Differentiation and Morphologic Subtypes. Surg. Pathol. Clin. 2022, 15, 641–659. [Google Scholar] [CrossRef]
- Taylor, J.M.; Bochner, B.; Amin, M.B.; Hansel, D.E. Muscle-invasive urothelial carcinoma: Conventional and variant subtypes. In The Urinary Tract: A Comprehensive Guide to Patient Diagnosis and Management; Springer: New York, NY, USA, 2012; pp. 143–163. [Google Scholar]
- Weyerer, V.; Eckstein, M.; Compérat, E.; Juette, H.; Gaisa, N.T.; Allory, Y.; Stöhr, R.; Wullich, B.; Rouprêt, M.; Hartmann, A.; et al. Pure large nested variant of urothelial carcinoma (LNUC) is the prototype of an FGFR3 mutated aggressive urothelial carcinoma with luminal-papillary phenotype. Cancers 2020, 12, 763. [Google Scholar] [CrossRef] [Green Version]
- Erck, A.; Li, W.; Movahedi-Lankarani, S.; Chung, S.; Aragon-Ching, J.B. Plasmacytoid variant of urothelial carcinoma: Poor prognostic variant with high expression of CDH1 mutation. Uro 2021, 1, 23–29. [Google Scholar] [CrossRef]
- Bennett, W.P.; Hollstein, M.C.; Hsu, I.C.; Sidransky, D.; Lane, D.P.; Vogelstein, B.; Harris, C.C. Mutational spectra and immunohistochemical analyses of p53 in human cancers. Chest 1992, 101, 19S–20S. [Google Scholar] [CrossRef] [Green Version]
- Chatterjee, S.J.; Datar, R.; Youssefzadeh, D.; George, B.; Goebell, P.J.; Stein, J.P.; Young, L.; Shi, S.-R.; Gee, C.; Groshen, S.; et al. Combined Effects of p53, p21, and pRb Expression in the Progression of Bladder Transitional Cell Carcinoma. JCO 2004, 22, 1007–1013. [Google Scholar] [CrossRef]
- Lorenzo-Romero, J.G.; Salinas-Sanchez, A.S.; Gimenez-Bachs, J.M.; Sánchez-Sánchez, F.; Escribano-Martínez, J.; Segura-Martín, M.; Hernandez-Millán, I.R.; Virseda-Rodríguez, J.A. Prognostic implications of p53 gene mutations in bladder tumors. J. Urol. 2003, 169, 492–499. [Google Scholar] [CrossRef]
- Hodgson, A.; Xu, B.; Downes, M.R. p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant. Histopathology 2017, 71, 296–304. [Google Scholar] [CrossRef]
- Yang, C.H.; Weng, W.C.; Ou, Y.C.; Lin, Y.S.; Huang, L.H.; Lu, C.H.; Tsao, T.Y.; Hsu, C.Y.; Tung, M.C. Diffusive Ki67 and vimentin are associated with worse recurrence-free survival of upper tract urothelial carcinoma: A retrospective cohort study from bench to bedside. Urol. Oncol. Semin. Orig. Investig. 2022, 40, 109.e21–109.e30. [Google Scholar] [CrossRef]
- Liao, Y.; Tang, H.; Wang, M.; Wang, K.; Wang, Y.; Jiang, N. The potential diagnosis role of TP53 mutation in advanced bladder cancer: A meta-analysis. J. Clin. Lab. Anal. 2021, 35, e23765. [Google Scholar] [CrossRef]
- Saint, F.; Belda, M.-A.L.F.; Quintela, R.; Hoznek, A.; Patard, J.-J.; Bellot, J.; Popov, Z.; Zafrani, E.S.; Abbou, C.C.; Chopin, D.K.; et al. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with bacillus calmette-guérin (BCG). Eur. Urol. 2004, 45, 475–482. [Google Scholar] [CrossRef]
- Du, J.; Wang, S.-H.; Yang, Q.; Chen, Q.-Q.; Yao, X. p53 status correlates with the risk of progression in stage T1 bladder cancer: A meta-analysis. World J. Surg. Oncol. 2016, 14, 137. [Google Scholar] [CrossRef] [Green Version]
- Shiina, H.; Igawa, M.; Shigeno, K.; Yamasaki, Y.; Urakami, S.; Yoneda, T.; Wada, Y.; Honda, S.; Nagasaki, M. Clinical significance of mdm2 and p53 expression in bladder cancer: A comparison with cell proliferation and apoptosis. Oncology 1999, 56, 239–247. [Google Scholar] [CrossRef]
- Toll, A.D.; Epstein, J.I. Invasive low-grade papillary urothelial carcinoma: A clinicopathologic analysis of 41 cases. Am. J. Surg. Pathol. 2012, 36, 1081–1086. [Google Scholar] [CrossRef]
- Wang, F.; Dong, X.; Yang, F.; Xing, N. Comparative Analysis of Differentially Mutated Genes in Non-Muscle and Muscle-Invasive Bladder Cancer in the Chinese Population by Whole Exome Sequencing. Front. Genet. 2022, 13, 831146. [Google Scholar] [CrossRef]
- Tian, W.; Epstein, J.I. Invasive low-grade papillary urothelial carcinoma: An immunohistochemical study of 26 cases. Hum. Pathol. 2015, 46, 1836–1841. [Google Scholar] [CrossRef]
- Enache, M.; Simionescu, C.; Lascu, L.C. Ki67 and Bcl-2 immunoexpression in primitive urothelial bladder carcinoma. Rom. J. Morphol. Embryol. 2012, 53, 521–525. [Google Scholar]
- Quintero, A.; Alvarez-Kindelan, J.; Luque, R.J.; Gonzalez-Campora, R.; Requena, M.J.; Montironi, R.; Lopez-Beltran, A. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J. Clin. Pathol. 2006, 59, 83–88. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Helpap, B.; Köllermann, J. Assessment of basal cell status and proliferative patterns in flat and papillary urothelial lesions: A contribution to the new WHO classification of urothelial tumors of the urinary bladder. Hum. Pathol. 2000, 31, 745–750. [Google Scholar] [CrossRef] [PubMed]
- Tsai, M.-Y.; Chiang, P.-C.; Chen, C.-H.; Sung, M.-T.; Huang, S.-C.; Suen, J.-L.; Tsai, E.-M.; Chiang, P.-H. Comparison of the Prognostic Value of Ki-67 and Programmed Cell Death Ligand-1 in Patients with Upper Tract Urothelial Carcinoma. J. Clin. Med. 2021, 10, 3728. [Google Scholar] [CrossRef]
- Krabbe, L.M.; Bagrodia, A.; Haddad, A.Q.; Kapur, P.; Khalil, D.; Hynan, L.S.; Wood, C.G.; Karam, J.A.; Weizer, A.Z.; Raman, J.D.; et al. Multi-institutional validation of the predictive value of Ki-67 in patients with high grade urothelial carcinoma of the upper urinary tract. J. Urol. 2015, 193, 1486–1493. [Google Scholar] [CrossRef]
- Lopez-Beltran, A.; Luque, R.J.; Alvarez-Kindelan, J.; Quintero, A.; Merlo, F.; Requena, M.J.; Montironi, R. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: The role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. Am. J. Clin. Pathol. 2004, 122, 444–452. [Google Scholar] [CrossRef] [PubMed]
- Ko, K.; Jeong, C.W.; Kwak, C.; Kim, H.H.; Ku, J.H. Significance of Ki-67 in non-muscle invasive bladder cancer patients: A systematic review and meta-analysis. Oncotarget 2017, 8, 100614–100630. [Google Scholar] [CrossRef] [Green Version]
- Rodríguez-Alonso, A.; Pita-Fernández, S.; González-Carreró, J.; Nogueira-March, J.L. p53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma. Eur. Urol. 2002, 41, 182–189. [Google Scholar] [CrossRef]
- Wahab, A.H.; Mohammed, M.A. Homozygous deletion of p16 gene in primary bladder and breast carcinomas in Egyptian cancer patients. J. Egypt. Nat. Cancer Inst. 2000, 12, 23–28. [Google Scholar]
- Mao, X.; Li, B.; Liang, Y.; Li, S.; Zhou, J.; He, Q.; Jiang, N.; Chen, Y.; Sun, Y.; Cui, Y.; et al. Auxiliary diagnostic value of p16 amplification combined with the detection of heterozygous and homozygous loss for urothelial carcinoma. Oncol. Lett. 2018, 15, 6533–6540. [Google Scholar] [CrossRef] [Green Version]
- Hashmi, A.A.; Hussain, Z.F.; Irfan, M.; Hashmi, S.K.; Asif, H.; Faridi, N. Prognostic significance of p16 immunohistochemical expression in urothelial carcinoma. Surg. Exp. Pathol. 2019, 2, 3. [Google Scholar] [CrossRef]
- Pu, X.; Zhu, L.; Fu, Y.; Fan, Z.; Zheng, J.; Zhang, B.; Yang, J.; Guan, W.; Wu, H.; Ye, Q.; et al. Companied P16 genetic and protein status together providing useful information on the clinical outcome of urinary bladder cancer. Medicine 2018, 9, e0353. [Google Scholar] [CrossRef] [PubMed]
- Hafez, F.S.; Meckawy, G.R.; Alorabi, M.; Shakweer, M.M. Interpretation of P16 expression as a marker of HPV in colorectal cancer. Histol. Histopathol. 2022, 37, 475–481. [Google Scholar] [CrossRef] [PubMed]
- Hasan, A.; Kandil, A.M.; Al-Ghamdi, H.S.; Alghamdi, M.A.; Nasr, M.; Naeem, S.A.; Abd-Elhay, W.M.; Mohamed, O.K.E.; Ibrahim, H.S.A.; Ahmed, E.M.; et al. Sun-Exposed versus Sun-Protected Cutaneous Basal Cell Carcinoma: Clinico-Pathological Profile and p16 Immunostaining. Diagnostics 2023, 13, 1271. [Google Scholar] [CrossRef] [PubMed]
- Hosny, G.; Ahmed, O.A.; Ahmed, R.M.; Fadel, S.A. Expression of p16 Tumor Suppressor Protein in Malignant Ovarian Germ Cell Tumors; Immunohistochemical Study. Int. J. Surg. Pathol. 2023, 11, 10668969231168358. [Google Scholar] [CrossRef]
- El Sokkary, H.H.; Sheta, E. Prevalence of P16 Immunohistochemistry Positive Staining and Its Correlation to Clinical and Radiological Staging of Squamous Cell Carcinoma of the Cervix. J. Obstet. Gynecol. India 2023. [Google Scholar] [CrossRef]
Mean | ±SD | Range | p-Value | |
---|---|---|---|---|
Grade | ||||
-Low grade | 9.1 | 9.6 | 1–30 | <0.005 |
-High grade | 17.6 | 12.8 | 5–65 | |
Stage | ||||
-T1 (NMIBC) | 8.8 | 6.4 | 2–30 | <0.005 |
-T2 (MIBC) | 23.9 | 16.3 | 3–65 | |
Pattern | ||||
-Papillary | 9.8 | 6.7 | 1–30 | <0.005 |
-Non-papillary | 17.7 | 15.3 | 2–65 |
Total N (%) | p16 | p Value | p53 | Ki-67 | p Value | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Negative, N (%) | Weak, N (%) | Moderate, N (%) | Strong, N (%) | Negative, N (%) | Positive, N (%) | p Value | Low Index, N (%) | High Index, N (%) | |||||
Diagnosis | Papillary UC | 30 (48.4%) | 13 (21.0%) | 1 (1.6%) | 7 (11.3%) | 9 (14.5%) | 26 (41.9%) | 4 (6.5%) | 23 (37.1%) | 7 (11.3%) | |||
Non-papillary UC | 32 (51.6%) | 15 (24.2%) | 2 (3.2%) | 4 (6.5%) | 11 (17.7%) | 27 (43.5%) | 5 (8.1%) | 18 (29.0%) | 14 (22.6%) | ||||
Total | 62 (100%) | 28 (45.2%) | 3 (4.8%) | 11 (17.7%) | 20 (32.3%) | 0.69 | 53 (85.5%) | 9 (14.5%) | 0.54 | 41 (66.1%) | 21 (33.9%) | 0.07 | |
Grade | High grade | 34 (54.8%) | 14 (22.6%) | 1 (1.6%) | 10 (16.1%) | 9 (14.5%) | 29 (46.8%) | 5 (8.1%) | 25 (40.3%) | 9 (14.5%) | |||
Low grade | 28 (45.2%) | 14 (22.6%) | 2 (3.2%) | 1 (1.6%) | 11 (17.7%) | 24 (38.7%) | 4 (6.5%) | 16 (25.8%) | 12 (19.4%) | ||||
Total | 62 (100.0%) | 28 (45.2%) | 3 (4.8%) | 11 (17.7%) | 20 (32.3%) | 0.24 | 53 (85.5%) | 9 (14.5%) | 0.06 | 41 (66.1%) | 21 (33.9%) | 0.69 | |
Stage | Stage pT1 | 32 (51.6%) | 15 (24.2%) | 0 (0.0%) | 8 (12.9%) | 9 (14.5%) | 27 (43.5%) | 5 (8.1%) | 24 (38.7%) | 8 (12.9%) | |||
Stage pT2 | 30 (48.4%) | 13 (21.0%) | 3 (4.8%) | 3 (4.8%) | 11 (17.7%) | 26 (41.9%) | 4 (6.5%) | 17 (27.4%) | 13 (21.0%) | ||||
Total | 62 (100.0%) | 28 (45.2%) | 3 (4.8%) | 11 (17.7%) | 20 (32.3%) | 0.13 | 53 (85.5%) | 9 (14.5%) | 0.54 | 41 (66.1%) | 21 (33.9%) | 0.1 |
p16 | Total | ||||||
---|---|---|---|---|---|---|---|
Negative | Weak Nuclear | Moderate Nuclear | Strong Nuclear | ||||
Grade | High grade | Count | 9 | 0 | 7 | 3 | 19 |
% within Grade | 47.4% | 0.0% | 36.8% | 15.8% | 100.0% | ||
% within p16 | 69.2% | 0.0% | 100.0% | 33.3% | 63.3% | ||
% of papillary | 30.0% | 0.0% | 23.3% | 10.0% | 63.3% | ||
Low grade | Count | 4 | 1 | 0 | 6 | 11 | |
% within Grade | 36.4% | 9.1% | 0.0% | 54.5% | 100.0% | ||
% within p16 | 30.8% | 100.0% | 0.0% | 66.7% | 36.7% | ||
% of papillary | 13.3% | 3.3% | 0.0% | 20.0% | 36.7% | ||
Total | Count | 13 | 1 | 7 | 9 | 30 | |
% within Grade | 43.3% | 3.3% | 23.3% | 30.0% | 100.0% | ||
% within p16 | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | ||
% of papillary | 43.3% | 3.3% | 23.3% | 30.0% | 100.0% |
p16 | Total | ||||||
---|---|---|---|---|---|---|---|
Negative | Weak Nuclear | Moderate Nuclear | Strong Nuclear | ||||
Stage | Stage pT1 | Count | 12 | 0 | 7 | 6 | 25 |
% within Stage | 48.0% | 0.0% | 28.0% | 24.0% | 100.0% | ||
% within p16 | 92.3% | 0.0% | 100.0% | 66.7% | 83.3% | ||
% of Total | 40.0% | 0.0% | 23.3% | 20.0% | 83.3% | ||
Stage pT2 | Count | 1 | 1 | 0 | 3 | 5 | |
% within Stage | 20.0% | 20.0% | 0.0% | 60.0% | 100.0% | ||
% within p16 | 7.7% | 100.0% | 0.0% | 33.3% | 16.7% | ||
% of Total | 3.3% | 3.3% | 0.0% | 10.0% | 16.7% | ||
Total | Count | 13 | 1 | 7 | 9 | 30 | |
% within Stage | 43.3% | 3.3% | 23.3% | 30.0% | 100.0% | ||
% within p16 | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | ||
% of Total | 43.3% | 3.3% | 23.3% | 30.0% | 100.0% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hasan, A.; Mohammed, Y.; Basiony, M.; Hanbazazh, M.; Samman, A.; Abdelaleem, M.F.; Nasr, M.; Abozeid, H.; Mohamed, H.I.; Faisal, M.; et al. Clinico-Pathological Features and Immunohistochemical Comparison of p16, p53, and Ki-67 Expression in Muscle-Invasive and Non-Muscle-Invasive Conventional Urothelial Bladder Carcinoma. Clin. Pract. 2023, 13, 806-819. https://doi.org/10.3390/clinpract13040073
Hasan A, Mohammed Y, Basiony M, Hanbazazh M, Samman A, Abdelaleem MF, Nasr M, Abozeid H, Mohamed HI, Faisal M, et al. Clinico-Pathological Features and Immunohistochemical Comparison of p16, p53, and Ki-67 Expression in Muscle-Invasive and Non-Muscle-Invasive Conventional Urothelial Bladder Carcinoma. Clinics and Practice. 2023; 13(4):806-819. https://doi.org/10.3390/clinpract13040073
Chicago/Turabian StyleHasan, Abdulkarim, Yasien Mohammed, Mostafa Basiony, Mehenaz Hanbazazh, Abdulhadi Samman, Mohamed Fayek Abdelaleem, Mohamed Nasr, Hesham Abozeid, Hassan Ismail Mohamed, Mahmoud Faisal, and et al. 2023. "Clinico-Pathological Features and Immunohistochemical Comparison of p16, p53, and Ki-67 Expression in Muscle-Invasive and Non-Muscle-Invasive Conventional Urothelial Bladder Carcinoma" Clinics and Practice 13, no. 4: 806-819. https://doi.org/10.3390/clinpract13040073